SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla wins cancer drug patent case over Tarceva

10 Sep 2012 Evaluate

Pharma major, Cipla has won a landmark patent case against Swiss drug maker F Hoffmann-La Roche in the Delhi High Court on September 7, 2012 over the Indian company’s generic copy of lung cancer drug Tarceva after a four-year court battle.

As per the Delhi High Court, Cipla's drug - Erlocip did not violate the Roche patent on its anti-lung cancer medication Tarceva due to its different molecular make-up. Justice Manmohan Singh observed in his 280-page judgment that it had been scientifically proven that Cipla’s generic version was a polymorph B variant of Roche’s patented drug and that it didn’t actually infringe any patent in India.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×